1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023

Summary

Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. GlobalData estimates the 2013 sales for melanoma at approximately $1.34 billion across the 8MM covered in this report. The market will increase by four-fold over the forecast period, reaching $5.64 billion in 2023 at a CAGR of 15.5%. This growth will be driven by an increase in melanoma incident cases as well as the approval and uptake of premium-priced products, such as PD-1-targeting mAbs and BRAF/MEK inhibitor combinations. GlobalData expects, by the end of the forecast period, the checkpoint immunotherapy drug class to dominate the melanoma market (including both BRAF wild-type and mutation-positive patient segments) with an overall 67% share of the melanoma market.

The melanoma pipeline is strong; however, GlobalData expects none of these drugs to have a major impact on the overall melanoma market, as the market is crowded with effective immunotherapies and BRAF mutation-targeted agents. The challenge for new entrants into the melanoma market is to find patient populations that are currently underserved. One of the opportunities for the companies is to work cooperatively to develop novel combinations of immuno/targeted-therapies.

Highlights

Key Questions Answered

- The melanoma space is filled with the excitement of recently approved anti-PD-1 immunotherapies, which are expected to revolutionize the treatment landscape. What will be the impact of these newly approved drugs and their projected label expansions on the melanoma sales?
- As the melanoma market is getting increasingly crowded with multiple anti-PD-1 immunotherapies and BRAF mutation-targeted agents, opportunities for new entrants become limited. What R&D strategies are being used by drug makers to remain competitive?
- The survival of patients with metastatic melanoma remains short, especially for those who do not response to anti-PD-1 immunotherapies. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the melanoma market?

Key Findings

- One of the main drivers of the enormous expansion of the gout market will be the launch of premium-priced metastatic therapies, such as anti-PD-1 immunotherapy and BRAF/MEK inhibitor combinations. These drugs will extend treatment duration and replace cheaper, generic, chemotherapy regimens.
- Another strong driver will be the label extension of current therapies into the new settings; for example, PD-1s will garner label extension for the first-line treatment in 2015-16, and the metastatic brands are expected to be approved in the adjuvant setting in the second half of the forecast period.
- Companies are focusing on the development of combination immunotherapies, trying to improve the response rate and response duration of drugs.
- One of the largest unmet needs is a need for efficacious treatment options for BRAF wild-type patients. Approximately half of melanoma patients do not have BRAF mutations, and are therefore non-eligible for BRAF/MEK inhibitor treatments. Other unmet needs include therapies for PD-1 immunotherapy non-responders, adjuvant treatment for patients with resected melanoma, effective treatment for brain metastasis, and predictive markers for therapeutic response to immunotherapies.

Scope

- Overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized melanoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in six patient segments (including adjuvant, BRAF mutated and BRAF wild-type), forecast from 2013 to 2023.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the melanoma therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
- Analysis of the current and future market competition in the global melanoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global melanoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 27
2.3 Upcoming Related Reports 27
3 Disease Overview 28
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 28
3.1.3 Melanoma Biomarkers 29
3.2 Clinical Staging 30
3.3 Symptoms 32
3.4 Prognosis 32
3.5 Quality of Life 34
4 Epidemiology 35
4.1 Disease Background 35
4.2 Risk Factors and Comorbidities 35
4.3 Global Trends 38
4.3.1 US 39
4.3.2 5EU 39
4.3.3 Japan and Australia 39
4.4 Forecast Methodology 40
4.4.1 Sources Used 42
4.4.2 Sources Not Used 49
4.4.3 Forecast Assumptions and Methods 49
4.5 Epidemiological Forecast for Melanoma (2013-2023) 52
4.5.1 Diagnosed Incident Cases of Melanoma 52
4.5.2 Age-Specific Diagnosed Incident Cases of Melanoma 54
4.5.3 Sex-Specific Diagnosed Incident Cases of Melanoma Skin Cancer 56
4.5.4 Age-Standardized Diagnosed Incidence Rates 58
4.5.5 Pathological Stage at Diagnosis 60
4.5.6 Five-Year Diagnosed Prevalent Cases of Melanoma Skin Cancer 61
4.5.7 Five-Year Diagnosed Prevalent Cases of Melanoma Skin Cancer by Genetic Aberrations 63
4.6 Discussion 65
4.6.1 Epidemiological Forecast Insight 65
4.6.2 Limitations of the Analysis 66
4.6.3 Strengths of the Analysis 67
5 Disease Management 68
5.1 Diagnosis Overview 68
5.2 Treatment Overview 69
5.2.1 Localized Melanoma: Stage 0 to Stage IIC 71
5.2.2 Regional Melanoma: Stage IIIA to Stage IIIC 72
5.2.3 Unresectable and Metastatic Melanoma: Stage III and Stage IV 75
5.3 US 81
5.3.1 Screening and Diagnosis 82
5.3.2 Clinical Practices 84
5.4 France 86
5.4.1 Screening and Diagnosis 87
5.4.2 Clinical Practices 87
5.5 Germany 88
5.5.1 Screening and Diagnosis 89
5.5.2 Clinical Practices 90
5.6 Italy 93
5.6.1 Screening and Diagnosis 94
5.6.2 Clinical Practices 94
5.7 Spain 96
5.7.1 Screening and Diagnosis 97
5.7.2 Clinical Practices 97
5.8 UK 98
5.8.1 Screening and Diagnosis 99
5.8.2 Clinical Practices 99
5.9 Japan 101
5.9.1 Screening and Diagnosis 101
5.9.2 Clinical Practices 102
5.10 Australia 103
5.10.1 Screening and Diagnosis 104
5.10.2 Clinical Practices 105
6 Competitive Assessment 108
6.1 Overview 108
6.2 Interferon-based Adjuvant Therapies 110
6.2.1 Roferon-A (Interferon Alfa-2a) 110
6.2.2 Intron A (Interferon Alfa-2b) 114
6.2.3 Sylatron (Peginterferon Alfa-2b) 118
6.3 Immune Checkpoint Inhibitors 124
6.3.1 Yervoy (Ipilimumab) 124
6.3.2 Opdivo (Nivolumab) 134
6.3.3 Keytruda (Pembrolizumab) 143
6.4 BRAF Mutation-targeted Therapies 151
6.4.1 Zelboraf (Vemurafenib) 151
6.4.2 Tafinlar (Dabrafenib) 158
6.4.3 Mekinist (Trametinib) 164
6.5 Other Therapeutic Classes 176
7 Unmet Need and Opportunity 178
7.1 Overview 178
7.2 Therapeutic Options for BRAF Wild-Type Patients 180
7.2.1 Unmet Need 180
7.2.2 Gap Analysis 181
7.2.3 Opportunity 182
7.3 Therapies for Non-responders to PD-1 Immunotherapy 183
7.3.1 Unmet Need 183
7.3.2 Gap Analysis 184
7.3.3 Opportunity 186
7.4 Adjuvant Therapies for High-Risk Resectable Melanoma 188
7.4.1 Unmet Need 188
7.4.2 Gap Analysis 189
7.4.3 Opportunity 191
7.5 Effective Treatment for Brain Metastases 193
7.5.1 Unmet Need 193
7.5.2 Gap Analysis 194
7.5.3 Opportunity 196
7.6 Predictive Markers for Therapeutic Response to Immunotherapies 197
7.6.1 Unmet Need 197
7.6.2 Gap Analysis 198
7.6.3 Opportunity 200
8 Pipeline Assessment 201
8.1 Overview 201
8.2 Promising Drugs in Clinical Development 202
8.3 RAF/RAS/MEK Pathway-Targeting Therapies 204
8.3.1 Cobimetinib (GDC-0973) 204
8.3.2 Encorafenib (LGX818) 211
8.3.3 Binimetinib (MEK162) 217
8.4 Immune-Related Therapies 224
8.4.1 Talimogene Laherparepvec 224
8.4.2 Eltrapuldencel-T (NSB20) 232
8.4.3 Seviprotimut-L (POL-103A) 238
8.4.4 PV-10 244
8.5 Promising Drugs in Early-Stage Development 250
8.5.1 PI3K/Akt/mTOR Pathway-Targeting Therapies 250
8.5.2 Cell Cycle Checkpoint Inhibitors 252
8.5.3 Next-Generation BRAF Inhibitors 254
8.5.4 Immunotherapies 256
8.5.5 Antibody-Drug Conjugates 259
8.6 Other Drugs in Development 261
9 Current and Future Players 263
9.1 Overview 263
9.2 Trends in Corporate Strategy 266
9.3 Company Profiles 267
9.3.1 Bristol-Myers Squibb 267
9.3.2 Novartis 270
9.3.3 Roche 273
9.3.4 Merck 276
10 Market Outlook 280
10.1 Global Markets 280
10.1.1 Forecast 280
10.1.2 Drivers and Barriers — Global Issues 284
10.2 United States 286
10.2.1 Forecast 286
10.2.2 Key Events 290
10.2.3 Drivers and Barriers — US 291
10.3 5EU 293
10.3.1 Forecast 293
10.3.2 Key Events 297
10.3.3 Drivers and Barriers — France 298
10.3.4 Drivers and Barriers — Germany 300
10.3.5 Drivers and Barriers — Italy 301
10.3.6 Drivers and Barriers — Spain 303
10.3.7 Drivers and Barriers — UK 304
10.4 Japan 306
10.4.1 Forecast 306
10.4.2 Key Events 309
10.4.3 Drivers and Barriers — Japan 309
10.5 Australia 311
10.5.1 Forecast 311
10.5.2 Key Events 314
10.5.3 Drivers and Barriers — Australia 315
11 Appendix 317
11.1 Bibliography 317
11.2 Abbreviations 344
11.3 Methodology 349
11.4 Forecasting Methodology 349
11.4.1 Diagnosed Melanoma Patients 349
11.4.2 Percent Drug-Treated Patients 350
11.4.3 Drugs Included in Each Therapeutic Class 350
11.4.4 Launch and Patent Expiry Dates 351
11.4.5 General Pricing Assumptions 352
11.4.6 Average Body Weight and Surface Area Across the 8MM 353
11.4.7 Individual Drug Assumptions 354
11.4.8 Generic Erosion 368
11.4.9 Pricing of Pipeline Agents 368
11.5 Primary Research - KOLs Interviewed for this Report 370
11.6 Primary Research - Prescriber Survey 373
11.7 About the Authors 374
11.7.1 Analyst 374
11.7.2 Therapy Area Director 374
11.7.3 Epidemiologist 375
11.7.4 Global Head of Healthcare 375
11.8 About GlobalData 376
11.9 Disclaimer 376

1.1 List of Tables
Table 1: Stage Definitions for Melanoma 31
Table 2: The ABCED Rule of Melanoma Detection 32
Table 3: Prognosis of Melanoma 33
Table 4: Risk Factors and Comorbidities for Melanoma of the Skin 37
Table 5: Melanoma of the Skin Staging Definition Equivalencies 41
Table 6: 8MM, Sources of Melanoma of the Skin Incidence Data 42
Table 7: 8MM, Sources of Melanoma of the Skin Incident Cases by Pathological Stage at Diagnosis Data 44
Table 8: 8MM, Sources of Melanoma of the Skin Five-Year Diagnosed Prevalent Cases by Stage Data 45
Table 9: 8MM, Sources of Melanoma of the Skin Diagnosed Prevalent Cases by Genetic Aberration 46
Table 10: 8MM, Diagnosed Incident Cases of Melanoma of the Skin, Both Sexes, Ages ?20 Years, N, Select Years 2013-2023 53
Table 11: 8MM, Age-Specific Diagnosed Incident Cases of Melanoma of the Skin, N (Row%), 2013 55
Table 12: 8MM, Sex-Specific Diagnosed Incident Cases of Melanoma of the Skin, Ages ?20 Years, N (Row %), 2013 57
Table 13: Age-Standardized Diagnosed Incidence Rate (ASR) of Melanoma of the Skin, Men and Women, Ages ?20 Years, 2013 59
Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin, Both Sexes, ?20 years, N, Select Years 2013-2023 62
Table 15: Clinical Guidelines for Melanoma 70
Table 16: Most Prescribed Drugs for Melanoma by Class in the Global Markets, 2013 81
Table 17: Country Profile — US 82
Table 18: Country Profile — France 86
Table 19: Country Profile — Germany 89
Table 20: Country Profile — Italy 93
Table 21: Country Profile — Spain 96
Table 22: Country Profile — UK 98
Table 23: Country Profile — Japan 101
Table 24: Country Profile — Australia 103
Table 25: Leading Treatments for Melanoma, 2013 109
Table 26: Product Profile — Roferon-A 111
Table 27: Safety of Roferon-A 112
Table 28: Roferon-A SWOT Analysis, 2015 113
Table 29: Global Sales Forecast ($m) for Roferon-A, 2013-2023 114
Table 30: Product Profile — Intron A 115
Table 31: Efficacy of Intron A (E1684) 116
Table 32: Safety of Intron A (E1684, E1690, and E1694) 117
Table 33: Intron A SWOT Analysis, 2015 117
Table 34: Global Sales Forecast ($m) for Intron A, 2013-2023 118
Table 35: Product Profile — Sylatron 120
Table 36: Efficacy of Sylatron (EORTC 18991, NCT00006249) 121
Table 37: Head-to-Head Comparison Between Sylatron and Low-Dose Interferon 122
Table 38: Safety of Sylatron 123
Table 39: Sylatron SWOT Analysis, 2015 123
Table 40: Global Sales Forecast ($m) for Sylatron, 2013-2023 124
Table 41: Product Profile — Yervoy 126
Table 42: Efficacy of Yervoy 128
Table 43: Comparison of Higher Dose Yervoy and Dacarbazine (NCT00324155) 129
Table 44: Network Meta-analysis of Yervoy 130
Table 45: Safety of Yervoy at 3mg/kg (NCT00094653) 131
Table 46: Safety Data from Yervoy Dose-Escalation Study (NCT00289640) 132
Table 47: Yervoy SWOT Analysis, 2015 133
Table 48: Global Sales Forecast ($m) for Yervoy, 2013-2023 134
Table 49: Product Profile — Opdivo 137
Table 50: Efficacy of Opdivo 139
Table 51: Efficacy of Opdivo in BRAF Wild-Type Advanced Melanoma (NCT01721772) 140
Table 52: Safety Data from Opdivo Dose-Escalation Study (NCT00730639) 141
Table 53: Safety Data from the CheckMate-037 Trial (NCT01721746) 141
Table 54: Opdivo SWOT Analysis, 2015 142
Table 55: Global Sales Forecast ($m) for Opdivo, 2013-2023 143
Table 56: Product Profile - Keytruda 146
Table 57: Efficacy of Keytruda from KEYNOTE-001 (NCT01295827) 147
Table 58: Efficacy of Keytruda from KEYNOTE-002 (NCT01704287) 148
Table 59: Safety of Keytruda 149
Table 60: Keytruda SWOT Analysis, 2015 150
Table 61: Global Sales Forecasts ($m) for Keytruda, 2013-2023 151
Table 62: Product Profile — Zelboraf 153
Table 63: Efficacy of Zelboraf 155
Table 64: Safety of Zelboraf 156
Table 65: Zelboraf SWOT Analysis, 2015 157
Table 66: Global Sales Forecasts ($m) for Zelboraf, 2013-2023 158
Table 67: Product Profile — Tafinlar 160
Table 68: Efficacy of Tafinlar 161
Table 69: Safety of Tafinlar 162
Table 70: Tafinlar SWOT Analysis, 2015 163
Table 71: Global Sales Forecast ($m) for Tafinlar, 2013-2023 164
Table 72: Product Profile — Mekinist 167
Table 73: Efficacy of Mekinist 169
Table 74: Efficacy Results of the COMBI-d Trial (NCT01584648) 170
Table 75: Efficacy Results of the COMBI-v Trial (NCT01072175) 171
Table 76: Safety of Mekinist 172
Table 77: Safety Results of the COMBI-d trial (NCT01584648) 173
Table 78: Safety Results of the COMBI-v trial (NCT01584648) 174
Table 79: Mekinist SWOT Analysis, 2015 175
Table 80: Global Sales Forecasts ($m) for Mekinist, 2013-2023 176
Table 81: Summary of Minor Therapeutic Classes, 2013 177
Table 82: Unmet Needs and Opportunities in Melanoma 180
Table 83: Product Profile — Cobimetinib 206
Table 84: Efficacy of the Zelboraf/Cobimetinib Combination 207
Table 85: Safety of the Zelboraf/Cobimetinib Combination 208
Table 86: Cobimetinib SWOT Analysis, 2015 210
Table 87: Global Sales Forecast ($m) for Cobimetinib, 2013-2023 211
Table 88: Product Profile — Encorafenib 213
Table 89: Efficacy of Encorafenib 214
Table 90: Encorafenib SWOT Analysis, 2015 216
Table 91: Global Sales Forecasts ($m) for Encorafenib, 2013-2023 217
Table 92: Product Profile — Binimetinib 219
Table 93: Efficacy of Binimetinib (NCT01320085) 220
Table 94: Safety of Binimetinib (NCT01320085) 221
Table 95: Binimetinib SWOT Analysis, 2015 223
Table 96: Global Sales Forecasts ($m) for Binimetinib, 2013-2023 224
Table 97: Product Profile — Talimogene Laherparepvec 227
Table 98: Efficacy of Talimogene Laherparepvec 228
Table 99: Safety of Talimogene Laherparepvec 229
Table 100: Talimogene Laherparepvec SWOT Analysis, 2015 231
Table 101: Global Sales Forecast ($m) for Talimogene Laherparepvec, 2013-2023 232
Table 102: Product Profile - Eltrapuldencel-T 234
Table 103: Efficacy of Eltrapuldencel-T 235
Table 104: Eltrapuldencel-T SWOT Analysis, 2015 237
Table 105: Global Sales Forecast ($m) for Eltrapuldencel-T, 2013-2023 238
Table 106: Product Profile — Seviprotimut-L 240
Table 107: Efficacy of Seviprotimut-L 241
Table 108: Seviprotimut-L SWOT Analysis, 2015 243
Table 109: Global Sales Forecast ($m) for Seviprotimut-L, 2013-2023 244
Table 110: Product Profile — PV-10 245
Table 111: Efficacy of PV-10 246
Table 112: Safety of PV-10 247
Table 113: PV-10 SWOT Analysis, 2015 249
Table 114: Global Sales Forecast ($m) for PV-10, 2013-2023 250
Table 115: Clinical Settings of Early-Stage Drugs Targeting the PI3K/Akt/mTOR Pathway 252
Table 116: Clinical Settings of Early-Stage Drugs Targeting Cell Cycle Checkpoints 254
Table 117: Clinical Settings of Early-Stage Next-Generation BRAF Inhibitors 255
Table 118: Clinical Settings of Early-Stage Immunotherapies 259
Table 119: Clinical Settings of Early-Stage Antibody-drug Conjugates 260
Table 120: Drugs in Development, 2015 261
Table 121: Key Companies in the Melanoma Market in the 8MM, 2013-2023 264
Table 122: BMS' Melanoma Portfolio Assessment, 2015 269
Table 123: Novartis' Melanoma Portfolio Assessment, 2015 272
Table 124: Roche's Melanoma Portfolio Assessment, 2015 275
Table 125: Merck's Melanoma Portfolio Assessment, 2015 278
Table 126: Global Sales Forecast ($m) for Melanoma, 2013-2023 282
Table 127: Melanoma Market — Drivers and Barriers, 2015 284
Table 128: Sales Forecast ($m) for Melanoma in the United States, 2013-2023 288
Table 129: Key Events Impacting Sales for Melanoma in the United States, 2013-2023 290
Table 130: Melanoma Market in the United States - Drivers and Barriers, 2015 291
Table 131: Sales Forecast ($m) for Melanoma in the 5EU, 2013-2023 295
Table 132: Key Events Impacting Sales for Melanoma in the 5EU, 2013-2023 297
Table 133: Melanoma Market in France — Drivers and Barriers, 2015 298
Table 134: Melanoma Market in Germany — Drivers and Barriers, 2015 300
Table 135: Melanoma Market in Italy — Drivers and Barriers, 2015 301
Table 136: Melanoma Market in Spain — Drivers and Barriers, 2015 303
Table 137: Melanoma Market in the United Kingdom — Drivers and Barriers, 2015 304
Table 138: Sales Forecast ($m) for Melanoma in Japan, 2013-2023 308
Table 139: Key Events Impacting Sales for Melanoma in Japan, 2013-2023 309
Table 140: Melanoma Market in Japan - Drivers and Barriers, 2015 309
Table 141: Sales Forecast ($m) for Melanoma in Australia, 2013-2023 312
Table 142: Key Events Impacting Sales for Melanoma in Australia, 2013-2023 314
Table 143: Melanoma Market in Australia - Drivers and Barriers, 2015 315
Table 144: Key Launch Dates 351
Table 145: Key Patent Expiries 352
Table 146 Average Body Weight and Surface Area Across the 8MM 353
Table 147: High-Prescribing Physicians Surveyed by Country 373

1.2 List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of Melanoma of the Skin, Ages ?20 Years, Both Sexes, N, 2013-2023 53
Figure 2: Age-Specific Diagnosed Incident Cases of Melanoma of the Skin, Both Sexes, N, 2013 56
Figure 3: Sex-Specific Diagnosed Incident Cases of Melanoma of the Skin (N), 2013 58
Figure 4 : Age-Standardized Diagnosed Incidence Rate (ASR) of Melanoma of the Skin, Men and Women, Ages ?20 Years, 2013 60
Figure 5: Distribution of Incident Cases of Melanoma Skin Cancer by Stage at Diagnosis (%) 61
Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin, Both Sexes, Ages ?20 Years, N, 2013-2023 63
Figure 7: Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin with BRAF Mutations, Both Sexes, Ages ?20 Years, N, 2013 64
Figure 8: Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin with NRAS Mutations, Both Sexes, Ages ?20 Years, 2013 65
Figure 9: Treatment Flowchart for Localized Melanoma 72
Figure 10: Treatment Flowchart for Regional Melanoma 73
Figure 11: Treatment Flowchart for Recurrent Melanoma 75
Figure 12: Treatment Flowchart for Metastatic Melanoma 77
Figure 13: Yervoy's Development in Melanoma 127
Figure 14: Opdivo's Development in Melanoma 137
Figure 15: Keytruda's Development in Melanoma 146
Figure 16: Zelboraf's Development in Melanoma 154
Figure 17: Mekinist's Development in Melanoma 168
Figure 18: Melanoma — Phase III Pipeline, 2015 203
Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in Melanoma, 2013-2023 204
Figure 20: Cobimetinib's Development in Melanoma 206
Figure 21: Clinical and Commercial Positioning of Cobimetinib 209
Figure 22: Encorafenib's Development in Melanoma 213
Figure 23: Clinical and Commercial Positioning of Encorafenib 215
Figure 24: Binimetinib's Development in Melanoma 219
Figure 25: Clinical and Commercial Positioning of Binimetinib 222
Figure 26: Talimogene Laherparepvec's Development in Melanoma 227
Figure 27: Clinical and Commercial Positioning of Talimogene Laherparepvec 230
Figure 28: Eltrapuldencel-T's Development in Melanoma 234
Figure 29: Clinical and Commercial Positioning of Eltrapuldencel-T 236
Figure 30: Seviprotimut-L's Development in Melanoma 240
Figure 31: Clinical and Commercial Positioning of Seviprotimut-L 242
Figure 32: PV-10's Development in Melanoma 246
Figure 33: Clinical and Commercial Positioning of PV-10 248
Figure 34: Global Sales of Branded Products for Melanoma by Company, 2013-2023 265
Figure 35: Company Portfolio Gap Analysis in Melanoma, 2013-2023 266
Figure 36: Bristol-Myers Squibb SWOT Analysis in Melanoma, 2013-2023 270
Figure 37: Novartis SWOT Analysis in Melanoma, 2013-2023 273
Figure 38: Roche SWOT Analysis in Melanoma, 2013-2023 276
Figure 39: Merck SWOT Analysis in Melanoma, 2013-2023 279
Figure 40: Global Sales for Melanoma by Region, 2013-2023 283
Figure 41: Sales for Melanoma in the United States by Drug Class, 2013-2023 289
Figure 42: Sales for Melanoma in the EU by Drug Class, 2013-2023 296
Figure 43: Sales for Melanoma in Japan by Drug Class, 2023 308
Figure 44: Sales for Melanoma in Australia by Drug Class, 2013-2023 313

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
TCR/CAR-T Therapies in Oncology: Analytical Tool

TCR/CAR-T Therapies in Oncology: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the ...

Tumor Ablation Market by Technology, Mode of Treatment, Application - Global Forecast 2021

Tumor Ablation Market by Technology, Mode of Treatment, Application - Global Forecast 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global tumor ablation market is estimated to register a high CAGR of 12.5% during 2016-2021, and is expected to be valued at ~USD 580.1 million in 2021. Although mature markets (North America and Europe) ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.